PIERIS PHARMACEUTICALS, INC.

(PIRS)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
1.800 USD    0.00%
05/12PIERIS PHARMACEUTICALS, INC. Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K/A)
AQ
05/11PIERIS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/11TRANSCRIPT : Pieris Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 11, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pieris Doses First Patient in Phase 2 Gastric Cancer Trial of Cinrebafusp Alfa

01/14/2022 | 08:55am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 4.39% 298.85 Delayed Quote.8.19%
PIERIS PHARMACEUTICALS, INC. 0.00% 1.8 Delayed Quote.-52.38%
SEAGEN INC. -2.10% 139.64 Delayed Quote.-9.68%
All news about PIERIS PHARMACEUTICALS, INC.
05/12PIERIS PHARMACEUTICALS, INC. Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
05/11PIERIS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
05/11TRANSCRIPT : Pieris Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 11, 2022
CI
05/11PIERIS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation F..
AQ
05/11Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March..
CI
05/11PIERIS PHARMACEUTICALS : Q1 Earnings Snapshot
AQ
05/11NORTH AMERICAN MORNING BRIEFING : All Eyes on Key -2-
DJ
03/02PIERIS PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
03/01TRANSCRIPT : Pieris Pharmaceuticals, Inc., 2021 Earnings Call, Mar 01, 2022
CI
03/01PIERIS PHARMACEUTICALS : Reports Full-Year 2021 Financial Results and Provides Corporate U..
PU
More news
Analyst Recommendations on PIERIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 45,7 M - -
Net income 2022 -31,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,39x
Yield 2022 -
Capitalization 133 M 133 M -
Capi. / Sales 2022 2,92x
Capi. / Sales 2023 2,84x
Nbr of Employees 133
Free-Float 90,1%
Chart PIERIS PHARMACEUTICALS, INC.
Duration : Period :
Pieris Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PIERIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,80 $
Average target price 8,00 $
Spread / Average Target 344%
EPS Revisions
Managers and Directors
Stephen S. Yoder President, Chief Executive Officer & Director
Thomas Bures Senior VP, Chief Financial & Accounting Officer
James Arthur Geraghty Chairman
Hitto Kaufmann Chief Scientific Officer & Senior Vice President
Tim Demuth Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
PIERIS PHARMACEUTICALS, INC.-52.38%133
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612